GSK · GSK Plc ADR
United States · RS rating 55 · As of 2026-11-03
| Price | 48.70 USD |
|---|---|
| 1-day change | -0.9% |
| RS rating (overall / 1M / 3M / 12M) | 55 / 70 / 55 / 57 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 34 / 31 / 40 |
| Industry group (rank) | Medical-Diversified (4) |
| EPS growth Q/Q | -68.2% |
| Sales growth Q/Q | +0.8% |
| Distance from 52-week high | +20.4% |
| Market cap (USD) | $111.0B |